Abstract
Modulation by fatty acids of the cytotoxic effect of recombinant tumor necrosis factor alpha (TNF) toward WEHI 164 mouse fibrosarcoma cells has been examined. Preincubating the highly TNF-sensitive WEHI clone 13 cells for 44 hr with 50 μmol/L of 20∶5n−3, 22∶6n−3, 18∶3n−6, 20∶3n−6 or 20∶4n−6 reduced cell survival 22 hr after challenge with TNF (40 ng/L) by 65%, 72%, 60%, 98% and 85%, respectively. In comparison, 18∶3n−3, 18∶2n−6 and 18∶1n−9 had only negligible effects on TNF-induced toxicity. Different extent of fatty acid incorporation into cell total phospholipids or triglycerides could not explain the observed effects on TNF cytotoxicity, and the enhanced cytotoxicity could therefore not be explained merely by an increased unsaturation of the cell membranes. In addition to the fatty acid supplied, preincubation with 18∶2n−6, 18∶3n−6 or 18∶3n−3 also enriched the cells with 20∶2n−6, 20∶3n−6 and 20∶3n−3, respectively, most likely due to chain elongation. The results suggest that the WEHI cells have a low Δ6 desaturase activity, and that n−6 and n−3 acids must have at least 3 or 4 double bonds, respectively, to enhance TNF cytotoxicity in WEHI cells. Dexamethasone partly inhibited TNF-induced cytotoxicity, while cyclooxygenase, thromboxane synthetase or lipoxygenase inhibitors had no or negligible effects. The antioxidant butylated hydroxyanisole (BHA) completely inhibited TNF-induced cytotoxicity, while the structurally and functionally similar antioxidant butylated hydroxy-toluene had no such effect, indicating that BHA does not block TNF cytotoxicity through its antioxidant effect. The results suggest that TNF cytotoxicity involves, directly or indirectly, metabolism of long-chain polyun-saturated fatty acids, and we speculate that fatty acid metabolites are involved.
Similar content being viewed by others
Abbreviations
- BHA:
-
butylated hydroxyanisole
- BHT:
-
butylated hydroxytoluene
- ED50 :
-
defined as the TNF concentration that reduces cell density by 50%
- FAME:
-
fatty acid methyl ester(s)
- FCS-M:
-
RPMI-1640 medium containing 10% (v/v) heat-inactivated fetal calf serum, 2 mmol/L L-glutamine and 40 mg/L genetamicin
- GLC:
-
gas-liquid chromatography
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- NDGA:
-
nordihydroguaretic acid
- SDS:
-
sodium dodecyl sulfate
- TLC:
-
thin-layer chromatography
- TNF:
-
recombinant murine tumor necrosis factor alpha
References
Le, J., and Vilček, J. (1987)Lab. Invest. 56 234–248.
Nissen-Meyer, J., Austgulen, R., and Espevik, T. (1987)Cancer Res. 47, 2251–2258.
Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Palladino, Jr., M.A., and Shepard, H.M. (1985)Science 230, 943–945.
Urban, J.L., Shepard, H.M., Rothstein, J.L., Sugarman, B.J., and Schreiber, H. (1986)Proc. Natl. Acad. Sci. USA 83, 5233–5237.
Tsujimoto, M., Yip, Y.K., and Vilček, J. (1985)Proc. Natl. Acad. Sci. USA 82, 7626–7630.
Johnson, S.E., and Baglioni, C. (1988)J. Biol. Chem. 263, 5686–5692.
Creasy, A.A., Yamamoto, R., and Vitt, C.R. (1987)Proc. Natl. Acad. Sci. USA 84, 3293–3297.
Zimmermann, R.J., Marafino, B.J., Chan, A., Landre, P., and Winkelhake, J.L. (1989)J. Immunol. 142, 1405–1409.
Kull, F.C. (1988)Biochem. Biophys. Res. Commun. 153, 402–409.
Hepburn, A., Boeynaems, J.M., Fiers, W., and Dumont, J.E. (1987)Biochem. Biophys. Res. Commun. 149, 815–822.
Suffys, P., Beyaert, R., Van Roy, F., and Fiers, W. (1987)Biochem. Biophys. Res. Commun. 149, 735–743.
Nielsen, N.H., and Hansen, J.P.H. (1980)J. Cancer. Res. Clin. Oncol. 98, 287–299.
Carroll, K.K., and Braden, L.M. (1986)Prog. Lipid Res. 25, 583–585.
Welsch, C.W. (1987)Am. J. Clin. Nutr. 45, 192–202.
Schlager, S.I., and Ohanian, S.H. (1979)J. Immunol. 123, 146–152.
Espevik, T., and Nissen-Meyer, J. (1986)J. Immunol. Methods 95, 99–105.
Metcalf, L.D., and Schmitz, A.A. (1961)Anal. Chem. 33, 363–364.
Mosmann, T. (1983)J. Immunol. Methods 65, 55–63.
Brunner, K.T., Mauel, J., Cerottini, J.C., and Chapuis, B. (1968)Immunology 14, 181–196.
Kaluzny, M.A., Duncan, L.A., Merritt, M.V., and Epps, D.E. (1985)J. Lipid Res. 26, 135–140.
Bjerve, K.S., Fischer, S., and Alme, K. (1987)Am. J. Clin. Nutr. 46, 570–576.
Bligh, E.G., and Dyer, W.J. (1959)Can. J. Biochem. Physiol. 37, 911–917.
Mangold, H.K. (1962) inDünnschichtchromatographie (Stahl, E., ed.) pp. 156–158, Springer-Verlag, Berlin.
Yamauchi, N., Kuriyama, H., Watanabe, N., Neda, H., Maeda, M., and Niitsu, Y. (1989)Cancer Res. 49, 1671–1675.
Bernert, Jr., J.T., and Sprecher, H. (1975)Biochim. Biophys. Acta 398, 354–363.
Reid, T., Ramesha, C.S., and Ringold, G.M. (1991)J. Biol. Chem. 266, 16580–16586.
Das, U.N., Begin, M.E., Ells, G., Huang, Y.S., and Horrobin, D.F. (1987)Biochem. Biophys. Res. Commun. 145, 15–24.
Begin, M.E., Das, U.N., Ells, G., and Horrobin, D.F. (1985)Prostagl. Leukotr. Med. 19, 177–186.
Chow, S.C., Sisfontes, L., Björkhem, I., and Jondal, M. (1989)Lipids 24, 700–704.
Matthews, N., Neale, M.L., Jackson, S.K., and Stark, J.M. (1987)Immunology 62, 153–155.
Watanabe, N., Niitsu, Y., Neda, H., Sone, H., Yamauchi, N., Maeda, M., and Urushizaki, I. (1988)Immunopharmacol. Immunotoxicol. 10, 109–116.
Schewe, T., Kühn, H., and Rapoport, S.M. (1987) inProstaglandins and Related Substances: A Practical Approach (Benedetto, C., McDonald-Gibson, R.G., Nigam, S. and Slater, T.F., eds.) pp. 229–242, IRL Press, Oxford.
Thompson, D., and Eling, T. (1989)Molec. Pharmacol. 36, 809–817.
Hori, T., Kashiyama, S., Hayakawa, M., Shibamoto, S., Tsujimoto, M., Oku, N., and Ito, F. (1989)Exp. Cell. Res. 185, 41–49.
Author information
Authors and Affiliations
About this article
Cite this article
Brekke, OL., Espevik, T., Bardal, T. et al. Effects of n−3 and n−6 fatty acids on tumor necrosis factor cytotoxicity in WEHI fibrosarcoma cells. Lipids 27, 161–168 (1992). https://doi.org/10.1007/BF02536172
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02536172